Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies

Published:October 15, 2020DOI:


      To measure the association between market-level promotional payments to urologists by the manufacturers of abiraterone and enzalutamide and national prescribing patterns.


      A 20% national sample of the 2015 Part D event file was used to identify patients filling their first prescription for abiraterone and enzalutamide and their prescribing physicians. The 2015 Open Payments data were used to characterize promotional payments made to physicians at the market level. Generalized linear models were then used to measure the relationship between market-level payments to urologists and the physician specialty prescribing abiraterone or enzalutamide for the first time


      In 2015, 2318 men filled a prescription for abiraterone or enzalutamide by a urologist or medical oncologist. Increasing market-level promotional payments to urologists for abiraterone or enzalutamide was strongly associated with a urologist prescribing either drug—24.3% versus 5.8% of those residing in the markets with highest and lowest level of promotional payments to urologists, respectively (P <.01). Neither the number of urologists residing in a market nor other promotional payment measures (ie, to medical oncologists for these drugs, or to all physicians for all other drugs) were associated with a urologist prescribing either drug.


      Promotional payments to urologists at the market level are strongly associated with the specialty of the physician prescribing abiraterone or enzalutamide for the first time. Future work should elucidate the effects of the shift in prescribing patterns on quality of care and financial hardship for men with advanced prostate cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • NCI
        Prostate Cancer Costs of Care Projections.
        Washington, DC, 2016 (Accessed May 4, 2016)
        • Scher HI
        • Fizazi K
        • Saad F
        • et al.
        Increased survival with enzalutamide in prostate cancer after chemotherapy.
        N Engl J Med. 2012; 367: 1187-1197
        • de Bono JS
        • Logothetis CJ
        • Molina A
        • et al.
        Abiraterone and increased survival in metastatic prostate cancer.
        N Engl J Med. 2011; 364: 1995-2005
        • Harland S
        • Staffurth J
        • Molina A
        • et al.
        Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
        Eur J Cancer. 2013; 49: 3648-3657
        • Basch E
        • Autio K
        • Ryan CJ
        • et al.
        Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
        Lancet Oncol. 2013; 14: 1193-1199
        • Cella D
        • Ivanescu C
        • Holmstrom S
        • Bui CN
        • Spalding J
        • Fizazi K
        Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.
        Ann Oncol. 2015; 26: 179-185
        • Fizazi K
        • Scher HI
        • Miller K
        • et al.
        Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
        Lancet Oncol. 2014; 15: 1147-1156
        • Tonyali S
        • Haberal HB
        • Sogutdelen E
        Toxicity, adverse events, and quality of life associated with the treatment of metastatic castration-resistant prostate cancer.
        Curr Urol. 2017; 10: 169-173
        • Caram MEV
        • Kaufman SR
        • Modi PK
        • et al.
        Adoption of abiraterone and enzalutamide by urologists.
        Urology. 2019; : 176-183
        • Casalino LP
        • Devers KJ
        • Brewster LR
        Focused factories? Physician-owned specialty facilities.
        Health Aff. 2003; 2: 56-67
        • Shactman D
        Specialty hospitals, ambulatory surgery centers, and general hospitals: charting a wise public policy course.
        Health Aff. 2005; 24: 868-873
        • Keating NL
        • O'Malley AJ
        • Freedland SJ
        • Smith MR
        Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
        J Natl Cancer Inst. 2010; 102: 39-46
        • Keating NL
        • O'Malley AJ
        • Smith MR
        Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
        J Clin Oncol. 2006; 24: 4448-4456
        • Shahinian VB
        • Kuo Y-F
        • Freeman JL
        • Goodwin JS
        Risk of fracture after androgen deprivation for prostate cancer.
        N Engl J Med. 2005; 352: 154-164
        • Ross RW
        • Small EJ.
        Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
        J Urol. 2002; 167: 1952-1956
        • Holmstrom S
        • Naidoo S
        • Turnbull J
        • Hawryluk E
        • Paty J
        • Morlock R
        Symptoms and impacts in metastatic castration-resistant prostate cancer: qualitative findings from patient and physician interviews.
        Patient. 2019; 12: 57-67
        • Sartor O
        • Flood E
        • Beusterien K
        • et al.
        Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations.
        Clin Genitourin Cancer. 2015; 13: 101-112
        • CMS
        Open Payments.
        Washington, DC, 2019 (Accessed October 23, 2019)
        • Diez Roux AV
        • Merkin SS
        • Arnett D
        • et al.
        Neighborhood of residence and incidence of coronary heart disease.[see comment].
        N Engl J Med. 2001; 345: 99-106
        • Bandari J
        • Ayyash OM
        • Turner 2nd, RM
        • Jacobs BL
        • Davies BJ
        The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
        Cancer. 2017; 123: 4356-4362
        • Albala DM
        • Kirsh GM
        • Shore ND
        Advanced prostate cancer in large group practices.
        Rev Urol. 2016; 18: 226-230
        • Crawford ED
        The role of the urologist in treating patients with hormone-refractory prostate cancer.
        Rev Urol. 2003; 5: S48-S52
        • Sartor AO
        • Fitzpatrick JM
        Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC).
        BJU Int. 2012; 110: 328-335
        • Shore ND
        Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?.
        Prostate Cancer Prostatic Dis. 2013; 16: 1-6
        • American Urological Association
        Castration-Resistant Prostate Cancer.
        Linthicum, MD, 2018 (Accessed April 14, 2019)
        • Elliott SP
        • Jarosek SL
        • Wilt TJ
        • Virnig BA
        Reduction in physician reimbursement and use of hormone therapy in prostate cancer.
        J Natl Cancer Inst. 2010; 102: 1826-1834
        • McKoy JM
        • Lyons EA
        • Obadina E
        • et al.
        Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.
        J Clin Oncol. 2005; 23: 8894-8905
        • Shahinian VB
        • Kuo YF
        • Gilbert SM
        • Freeman JL
        • Orihuela E
        • Goodwin JS
        Reimbursement policy and androgen-deprivation therapy for prostate cancer.
        N Engl J Med. 2010; 363: 1822-1832
        • Dinan MA
        • Li Y
        • Zhang Y
        • et al.
        Resource use in the last year of life among patients who died with versus of prostate cancer.
        Clin Genitourin Cancer. 2016; 14 (e22): 28-37
        • Shahinian VB
        • Kuo Y-F.
        Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
        J Gen Intern Med. 2013; 28: 1440-1446
        • Lee CW
        • Vitous CA
        • Silveira MJ
        • et al.
        Delays in palliative care referral among surgical patients: perspectives of surgical residents across the state of michigan.
        J Pain Symptom Manage. 2019; 57: 1080-1088
        • Suwanabol PA
        • Kanters AE
        • Reichstein AC
        • et al.
        Characterizing the role of U.S. surgeons in the provision of palliative care: a systematic review and mixed-methods meta-synthesis.
        J Pain Symptom Manage. 2018; 55 (e1195): 1196-1215
        • Suwanabol PA
        • Reichstein AC
        • Suzer-Gurtekin ZT
        • et al.
        Surgeons' perceived barriers to palliative and end-of-life care: a mixed methods study of a surgical society.
        J Palliat Med. 2018; 21: 780-788